PRKAA2 and metabolic dysfunction-associated steatotic liver disease: Since the activity of AMPK is reduced in obesity, increasing AMPK activity has been suggested as an attractive therapeutic option for obesity-associated metabolic diseases, including NAFLD/NASH8–10,19,20.